Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan.
Okamura A, Watanabe M, Okui J, Matsuda S, Takemura R, Kawakubo H, Takeuchi H, Muto M, Kakeji Y, Kitagawa Y, Doki Y. Okamura A, et al. Among authors: doki y. Ann Surg Oncol. 2023 Apr;30(4):2176-2185. doi: 10.1245/s10434-022-12960-9. Epub 2022 Dec 17. Ann Surg Oncol. 2023. PMID: 36528742
Is Thoracic Duct Resection Necessary for Esophageal Squamous Cell Carcinoma Patients Treated with Neoadjuvant Chemoradiotherapy? A Propensity-Matched Analysis Based on the Comprehensive Registry of Esophageal Cancer in Japan.
Oshikiri T, Numasaki H, Oguma J, Toh Y, Watanabe M, Muto M, Kakeji Y, Doki Y. Oshikiri T, et al. Among authors: doki y. Ann Surg Oncol. 2023 May;30(5):2691-2698. doi: 10.1245/s10434-022-12891-5. Epub 2022 Dec 18. Ann Surg Oncol. 2023. PMID: 36529778
[No title available]
[No authors listed] [No authors listed] PMID: 36602666
[No title available]
[No authors listed] [No authors listed] PMID: 36611068
A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer.
Matsuda C, Kudo T, Morimoto Y, Kagawa Y, Tei M, Ide Y, Miyoshi N, Takahashi H, Uemura M, Takemasa I, Satoh T, Mizushima T, Murata K, Doki Y, Eguchi H; Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MSCSGO). Matsuda C, et al. Among authors: doki y. Ann Gastroenterol Surg. 2022 Jul 15;7(1):81-90. doi: 10.1002/ags3.12600. eCollection 2023 Jan. Ann Gastroenterol Surg. 2022. PMID: 36643362 Free PMC article.
Neutrophil-to-lymphocyte ratio after neoadjuvant chemotherapy as an independent prognostic factor in patients with esophageal squamous cell carcinoma.
Yamada M, Tanaka K, Yamasaki M, Yamashita K, Makino T, Saito T, Takahashi T, Kurokawa Y, Motoori M, Kimura Y, Nakajima K, Eguchi H, Doki Y. Yamada M, et al. Among authors: doki y. Oncol Lett. 2022 Dec 20;25(2):58. doi: 10.3892/ol.2022.13644. eCollection 2023 Feb. Oncol Lett. 2022. PMID: 36644140 Free PMC article.
1,635 results